Besponsa (inotuzumab ozogamicin)

Besponsa (inotuzumab ozogamicin) approved for adults with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or recurrent.

B-cell precursor ALL, if not treated is probably fatal within a few months.

Besponsa is an antibody-drug conjugate, a monoclonal antibody linked to a chemotherapy drug.

Attaches to B-cell ALL cancer cells that express the CD22 protein, blocking the growth of cancer cells.

Inotuzumab targets the CD22 immunotoxin antigen via a T-cell independent process and is delivered as a once-weekly 1-hour infusion. 
It is approved for adult relapsed/refractory B-ALL. 

CD22 directed antibody drug conjugate.

It is intended to target and kill only the cancer cells and spare healthy cells.

Of patients evaluated in the INO-VATE trial, 35.8% who received the drug had a complete remission for an average of 8 months and 17.4% who received standard treatment had a complete remission for an average of 4.9 months.

Given as an intravenous infusion.

Common side effects include: low blood counts, fatigue, severe bleeding, fever, nausea, headache, abdominal pain, abnormal liver tests, and high levels of bilirubin in the blood.

Serious side effects include increased risk of severe liver damage in patients who receive this drug after certain kinds of stem cell transplant, infusion-related reactions, and heart problems.

It may cause harm to a developing fetus or a newborn baby.

Leave a Reply

Your email address will not be published.